New York, home to a quarter of U.S. cases of the deadly superbug C. auris, sits on the frontlines of rising antibiotic resistance – a crisis projected to kill 40 million people worldwide by 2050. Developing new antibiotics is slow, costly, and financially unsustainable for drugmakers, leaving patients vulnerable as existing treatments lose effectiveness. The bipartisan PASTEUR Act would guarantee drug developers stable contracts with the federal government, incentivizing innovation while ensuring patient access. For New York, a national biotech hub, passage of the act would both safeguard public health and drive significant economic growth.